Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: MAPP BIOPHARMACEUTICAL, INC.
Awarding agency: Department of Defense / Defense Threat Reduction Agency
Funding agency: Department of Defense / Defense Threat Reduction Agency
Period of performance: 2013-02-15 to 2017-08-31
Current total value of award: $11438073
Description: MB-2003: AN EBOLA VIRUS COUNTERMEASURE